Arixtra 2.5mg Injection
Prescription Required
Product introduction
Arixtra 2.5mg Injection is an anticoagulant medicine used in the treatment of deep vein thrombosis (clot in veins of leg) and pulmonary embolism (clot in artery of lungs). It helps to prevent formation of harmful blood clots in blood vessels.
Arixtra 2.5mg Injection is an anti-coagulant which helps prevent the formation of harmful blood clots in the legs, lungs, and heart. It is only available as an injection that is used under the skin. It can increase the risk of bleeding, so be careful while shaving, cutting nails, using sharp objects, or engaging in contact sports (e.g. football, wrestling). Let your doctor know if you see blood in your vomits, urine, or stool (black or tarry). Unlike other anti-coagulants, regular blood test (PT-INR) is not required while taking this medicine. It is important that this medicine is taken strictly according to the doctor’s advice and is not stopped abruptly.
Arixtra 2.5mg Injection is an anti-coagulant which helps prevent the formation of harmful blood clots in the legs, lungs, and heart. It is only available as an injection that is used under the skin. It can increase the risk of bleeding, so be careful while shaving, cutting nails, using sharp objects, or engaging in contact sports (e.g. football, wrestling). Let your doctor know if you see blood in your vomits, urine, or stool (black or tarry). Unlike other anti-coagulants, regular blood test (PT-INR) is not required while taking this medicine. It is important that this medicine is taken strictly according to the doctor’s advice and is not stopped abruptly.
Uses of Arixtra Injection
Benefits of Arixtra Injection
In Deep vein thrombosis
Deep vein thrombosis refers to the formation of a clot in a vein that is deeply located in the body. Arixtra 2.5mg Injection prevents blood from clotting inside the veins and arteries. This helps the blood flow freely around your body thereby preventing a heart attack or stroke (or deep vein thrombosis. It helps prevent the formation of blood clots and also prevents the existing ones from growing bigger in size. Make appropriate lifestyle changes (such as eating healthy and staying active) to maximize the effectiveness of this medicine.
In Pulmonary embolism
Pulmonary embolism refers to clotting of blood in your lungs. Arixtra 2.5mg Injection prevents this clot formation in your lungs. This helps the blood flow freely around your body thereby preventing a heart attack or stroke. It prevents the formation of blood clots and also prevents the existing ones from growing bigger in size. Make appropriate lifestyle changes (such as eating healthy and staying active) to maximize the effectiveness of this medicine. Follow your doctor’s instructions carefully to get maximum benefit.
Side effects of Arixtra Injection
Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them
Common side effects of Arixtra
- Bleeding
- Anemia (low number of red blood cells)
How to use Arixtra Injection
Your doctor or nurse will give you this medicine. Kindly do not self administer.
Safety advice
Alcohol
UNSAFE
It is unsafe to consume alcohol with Arixtra 2.5mg Injection.
Pregnancy
SAFE IF PRESCRIBED
Arixtra 2.5mg Injection is generally considered safe to use during pregnancy. Animal studies have shown low or no adverse effects to the developing baby; however, there are limited human studies.
Breast feeding
SAFE IF PRESCRIBED
Arixtra 2.5mg Injection is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
Driving
CONSULT YOUR DOCTOR
It is not known whether Arixtra 2.5mg Injection alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Kidney
CAUTION
Arixtra 2.5mg Injection should be used with caution in patients with kidney disease. Dose adjustment of Arixtra 2.5mg Injection may be needed. Please consult your doctor.
Use of Arixtra 2.5mg Injection is not recommended in patients with severe kidney disease.
Use of Arixtra 2.5mg Injection is not recommended in patients with severe kidney disease.
Liver
CAUTION
Arixtra 2.5mg Injection should be used with caution in patients with severe liver disease. Dose adjustment of Arixtra 2.5mg Injection may be needed. Please consult your doctor.
All substitutes
For informational purposes only. Consult a doctor before taking any medicines.
Arixtra 2.5mg Injection
₹680.0/Injection
Fondaflo 2.5 Injection
Lupin Ltd
₹948.35/injection
39% costlier
Fondared 2.5mg Injection
Dr Reddy's Laboratories Ltd
₹950.2/injection
40% costlier
Fondakem 2.5mg Injection
Alkem Laboratories Ltd
₹715/injection
5% costlier
Fondum 2.5mg Injection
Aristo Pharmaceuticals Pvt Ltd
₹853/injection
25% costlier
Fondastar 2.5mg Injection
Oaknet Healthcare Pvt Ltd
₹655/injection
4% cheaper
Quick tips
- Arixtra 2.5mg Injection prevents the formation of blood clots in the blood vessels of legs or lungs.
- It may make you feel dizzy, tired or weak. Do not drive or do anything that requires mental focus until you know how it affects you.
- It increases your risk of bleeding. Be careful while shaving, cutting fingernails or toenails, or using sharp objects.
- Notify your doctor if you see blood in your vomit, urine or stool (black, tarry stools or bright red blood).
- Do not discontinue use without consulting your doctor as this may increase your chances of having another heart attack or stroke.
Fact Box
Chemical Class
Synthetic Glucopyranoside
Habit Forming
No
Therapeutic Class
CARDIAC
Action Class
Selective inhibitor of activated Factor X
Patient concerns
FAQs
Q. Can the use of Arixtra 2.5mg Injection increase the risk of bleeding?
Yes, Arixtra 2.5mg Injection increases the risk of bleeding, and the affects of Arixtra 2.5mg Injection may last for 4 days even after stopping this medicine. Always be careful while doing activities that may cause an injury or bleeding. Tell your doctor immediately if you notice any abnormal bruising or bleeding.
Disclaimer:
Tata 1mg's sole intention is to ensure that its consumers get information that is expert-reviewed, accurate and trustworthy. However, the information contained herein should NOT be used as a substitute for the advice of a qualified physician. The information provided here is for informational purposes only. This may not cover everything about particular health conditions, lab tests, medicines, all possible side effects, drug interactions, warnings, alerts, etc. Please consult your doctor and discuss all your queries related to any disease or medicine. We intend to support, not replace, the doctor-patient relationship.References
- Fox KA, White HD, Gersh BJ, et al. Antithrombotic Agents: Platelete Inhibitors, Acute Anticoagulants, Fibrinolytics, and Chronic Anticoagulants. In: Opie LH, Gersh BJ, editors. Drugs for the Heart. 8th ed. Philadelphia, Pennsylvania: Elsevier Saunders; 2013. pp. 375-76.
- Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 591-92.
Marketer details
Name: Glaxo SmithKline Pharmaceuticals Ltd
Address: Dr. Annie Besant Road, Mumbai - 400 030
Country of origin: France
Lab tests offered by us
Related/Popular tests
DISCONTINUED
We do not facilitate sale of this product at present